PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel chec… Read more
PharmaEssentia - Asset Resilience Ratio
PharmaEssentia (6446) has an Asset Resilience Ratio of 0.07% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how PharmaEssentia's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down PharmaEssentia's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$21.96 Million | 0.07% |
| Total Liquid Assets | NT$21.96 Million | 0.07% |
Asset Resilience Insights
- Limited Liquidity: PharmaEssentia maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PharmaEssentia Industry Peers by Asset Resilience Ratio
Compare PharmaEssentia's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for PharmaEssentia (2014–2024)
The table below shows the annual Asset Resilience Ratio data for PharmaEssentia.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-09-30 | 0.08% | NT$23.64 Million | NT$31.06 Billion | -0.01pp |
| 2023-09-30 | 0.08% | NT$22.18 Million | NT$27.27 Billion | -6.29pp |
| 2022-09-30 | 6.37% | NT$976.25 Million | NT$15.33 Billion | +5.93pp |
| 2021-09-30 | 0.44% | NT$27.09 Million | NT$6.20 Billion | +0.22pp |
| 2020-09-30 | 0.22% | NT$12.00 Million | NT$5.53 Billion | +0.15pp |
| 2017-09-30 | 0.07% | NT$2.47 Million | NT$3.67 Billion | +0.01pp |
| 2016-09-30 | 0.05% | NT$2.47 Million | NT$4.50 Billion | -0.18pp |
| 2015-09-30 | 0.24% | NT$2.47 Million | NT$1.04 Billion | +0.09pp |
| 2014-09-30 | 0.15% | NT$2.47 Million | NT$1.66 Billion | -- |